Based on the revised guidance, the Company expects GAAP net income to be in the range of $133 to $146 million. The Company expects CNI, which adds back the after tax impact of book amortization of intangible assets and the amortization and write off of deferred financing costs, to be in the range of $346 to $359 million. Using 251.0 million Class A common shares, the Company anticipates CNI per share to be in the range of $1.38 to $1.43 for the full year 2008, an increase of $0.08 per share from the guidance given in August of 2008.
Investor Conference Call
The Company is hosting a conference call, open to all interested parties, on Monday, November 10, 2008 beginning at 8:00 AM EST. The number to call within the United States and Canada is (877) 856-1955. Participants outside the United States and Canada should call (719) 325-4798. A replay of the conference call will be available from two hours after the call through midnight EST on November 24, 2008 and can be accessed by dialing (888) 203-1112 from within the United States and Canada or (719) 457-0820 from outside the United States and Canada. The replay ID number is 6395194.
Warner Chilcott is a leading specialty pharmaceutical company currently focused on the women's healthcare and dermatology segments of the U.S. pharmaceuticals market. The Company is a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of its products. WCRX-F
Forward Looking Statements
This press release contains forward-looking statements, including
statements concerning our operations, our anticipated economic performance
and financial condition, and our business plans and growth strategy and
product development efforts. These statements constitute forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange
|SOURCE Warner Chilcott Limited|
Copyright©2008 PR Newswire.
All rights reserved